KRYSTAL BIOTECH INC.

Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference

03 май 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study

11 апр 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine

28 мар 2022 11:00:00 Источник Nasdaq GlobeNewswire

New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

26 мар 2022 12:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

24 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting

18 мар 2022 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Settlement with PeriphaGen, Inc.

15 мар 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference

24 фев 2022 07:00:03 Источник Nasdaq GlobeNewswire

Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors

18 янв 2022 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Pricing of $200 Million Public Offering of Common Stock

30 ноя 2021 20:15:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Proposed $200 Million Public Offering of Common Stock

29 ноя 2021 16:20:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa

29 ноя 2021 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress

08 ноя 2021 07:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa

26 окт 2021 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB407 for the Treatment of Cystic Fibrosis

19 окт 2021 16:05:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Announces Virtual Presentation of Pre-clinical Data on KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency at ESGCT

14 окт 2021 07:00:00 Источник Nasdaq GlobeNewswire

Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

12 окт 2021 08:00:02 Источник Nasdaq GlobeNewswire

Krystal Biotech to Present at the Chardan 5th Annual Genetic Medicines Conference

01 окт 2021 16:01:00 Источник Nasdaq GlobeNewswire

Krystal Biotech Receives Approval from the Human Research Ethics Committee in Australia for Phase 1 Trial of KB407 for Cystic Fibrosis

29 сен 2021 08:00:01 Источник Nasdaq GlobeNewswire

Krystal Biotech Appoints Laurent Goux as General Manager of Europe

15 сен 2021 08:00:01 Источник Nasdaq GlobeNewswire